

Normand Blais

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8473045/publications.pdf>

Version: 2024-02-01

38
papers

917
citations

516710

16
h-index

477307

29
g-index

38
all docs

38
docs citations

38
times ranked

1457
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>New England Journal of Medicine</i> , 2021, 385, 720-728.	27.0	156
2	A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1379-1391.	1.1	89
3	Immunotherapy Comes of Age in Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 13-22.	2.6	68
4	Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2021, 18, 104-114.	3.8	57
5	Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. <i>European Journal of Cancer</i> , 2021, 142, 83-91.	2.8	48
6	Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. <i>Lung Cancer</i> , 2016, 99, 123-126.	2.0	46
7	Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study. <i>Thrombosis Research</i> , 2014, 133, 48-51.	1.7	45
8	Management of stage III non-small cell lung cancer. <i>Seminars in Oncology</i> , 2017, 44, 163-177.	2.2	40
9	Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. <i>Thrombosis Research</i> , 2021, 205, 29-39.	1.7	35
10	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. <i>Current Oncology</i> , 2021, 28, 523-548.	2.2	31
11	Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection. <i>Thrombosis Research</i> , 2020, 196, 491-493.	1.7	28
12	Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine. <i>Frontiers in Oncology</i> , 2017, 7, 52.	2.8	26
13	Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada. <i>Canadian Urological Association Journal</i> , 2019, 14, E57-E64.	0.6	26
14	Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. <i>Current Oncology</i> , 2021, 28, 5434-5451.	2.2	26
15	Neurologic manifestations of Henoch-Schönlein purpura. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014, 120, 1101-1111.	1.8	24
16	Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an <i>HLA-DRB1-MET</i> Gene Fusion. <i>Oncologist</i> , 2020, 25, 916-920.	3.7	20
17	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. <i>Canadian Urological Association Journal</i> , 2018, 12, 173-80.	0.6	16
18	Immunotherapy in Extensive-Stage Small Cell Lung Cancer. <i>Current Oncology</i> , 2021, 28, 4093-4108.	2.2	15

#	ARTICLE	IF	CITATIONS
19	Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France. <i>Journal of Geriatric Oncology</i> , 2020, 11, 802-806.	1.0	14
20	Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 4981-4997.	2.2	14
21	Maintenance Therapies for Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 213.	2.8	13
22	Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC. <i>Current Oncology</i> , 2021, 28, 593-605.	2.2	10
23	Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 381-387.	2.3	8
24	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2019, 13, 318-327.	0.6	8
25	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. <i>Canadian Urological Association Journal</i> , 2020, 14, E373-E382.	0.6	8
26	Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib. <i>Current Oncology</i> , 2021, 28, 265-272.	2.2	7
27	Improvement of EGFR Testing over the Last Decade and Impact of Delaying TKI Initiation. <i>Current Oncology</i> , 2021, 28, 1045-1055.	2.2	7
28	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. <i>Canadian Urological Association Journal</i> , 2017, 11, 310-320.	0.6	6
29	A phase II trial combining nivolumab and stereotactic brain radiosurgery for treatment of brain metastases in patients with NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2023-2023.	1.6	6
30	Managing advanced penile cancer in 2014. <i>Current Opinion in Supportive and Palliative Care</i> , 2014, 8, 241-249.	1.3	5
31	The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and the influence of the NLR in NSCLC patients treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21010-e21010.	1.6	4
32	Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. <i>Current Oncology</i> , 2021, 28, 4552-4576.	2.2	4
33	Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC). <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 115-119.	1.7	4
34	Do Women Have Equal Chances for an Academic Career in Radiation Oncology in Canada? A Comparison With Related Specialties. <i>Advances in Radiation Oncology</i> , 2020, 5, 313-317.	1.2	2
35	Association between immune-related adverse events and microbiome composition in patients with advanced non-small cell lung cancer treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9036-9036.	1.6	1
36	High intensity interval training safety and efficacy in patients with advanced NSCLC receiving systemic treatment: Results of a prospective trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12054-12054.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.. Journal of Clinical Oncology, 2021, 39, e21198-e21198.	1.6	0
38	A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC). Cancer Treatment and Research Communications, 2021, 28, 100421.	1.7	0